Organizer
Phenomenex
Phenomenex
Phenomenex is a global technology leader committed to developing novel analytical chemistry solutions that solve the separation and purification challenges of researchers in industrial, government and academic laboratories. From drug discovery and pharmaceutical development to disease diagnosis, food safety to environmental analysis, Phenomenex chromatography solutions accelerate science and help researchers improve global health and well-being.
Tags
HPLC
Columns
Consumables
LinkedIn Logo

Symbiosis of Core-Shell and Fully Porous Particles

RECORD | Already taken place Tu, 22.4.2025
In this webinar you will find how best to utilize modern UHPLC particles to optimize chromatographic performance.
Go to the webinar
Phenomenex: Symbiosis of Core-Shell and Fully Porous Particles
Phenomenex: Symbiosis of Core-Shell and Fully Porous Particles

Key Learning Points

  • Find how best to utilize modern UHPLC particles to optimize chromatographic performance.
  • Learn when to consider particle morphologies as a method development tool. 
  • Learn when to consider phase selectivity as a method development tool. 

Who Should Attend

  • Any LC User who is interested in the performance benefits, and differences, of both core- shell and full porous particles.

Speaker: Sean Orlowicz (Principal Market Development Manager - Pharmaceutical, Phenomenex)

Sean Orlowicz has been working in the field of analytical chemistry for over 23yrs.  After receiving his degree in Chemistry from the University of Illinois at Chicago, he started his career in large scale synthesis, using HPLC and GC techniques in reaction monitoring and purification.  Sean took this experience to Phenomenex in 2003,  working on site with clients worldwide on method development, troubleshooting and method transfer.  Sean explored instrumentation for a few years, growing to specialize in LCMS, before returning to Phenomenex to help build and manage Phenomenex’s new applications laboratory.  Since then, Sean has been driving innovation and growth though Business Development efforts, and most recently, in 2025 Sean has taken a Market Development Management role, spearheading our global efforts in Pharmaceuticals.

Phenomenex
LinkedIn Logo
 

Related content

Early-stage drug metabolite quantitation without radiolabels

Applications
| 2026 | Thermo Fisher Scientific
Instrumentation
HPLC, LC/MS, LC/SQ
Manufacturer
Thermo Fisher Scientific
Industries
Pharma & Biopharma, Metabolomics

Oligonucleotide Analysis Using the Agilent InfinityLab Pro iQ and Altura Oligo HPH-C18 Column

Applications
| 2026 | Agilent Technologies
Instrumentation
LC/MS, LC/SQ, Consumables, LC columns
Manufacturer
Agilent Technologies
Industries
Pharma & Biopharma

Simultaneous Quantitation and Discovery analysis: Combining targeted and untargeted metabolomics on Orbitrap mass spectrometers

Applications
| 2026 | Thermo Fisher Scientific
Instrumentation
LC/MS, LC/MS/MS, LC/Orbitrap, LC/HRMS
Manufacturer
Thermo Fisher Scientific
Industries
Metabolomics

Analysis of Per- and Polyfluoroalkyl Substances (PFAS) in Wastewater

Applications
| 2026 | Agilent Technologies
Instrumentation
LC/MS, LC/MS/MS, LC/QQQ
Manufacturer
Agilent Technologies
Industries
Environmental

Non-Targeted Screening of Biosolids with the Xevo™ MRT Mass Spectrometer Reveals New Isoforms of PFAS

Applications
| 2026 | Waters
Instrumentation
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS
Manufacturer
Waters
Industries
Environmental
Other projects
GCMS
ICPMS
Follow us
FacebookX (Twitter)LinkedInYouTube
More information
WebinarsAbout usContact usTerms of use
LabRulez s.r.o. All rights reserved. Content available under a CC BY-SA 4.0 Attribution-ShareAlike